Business Context and Reporting Period
Company: Profound Medical Corp. (PROF)
Filing Type: Form 8-K (Current Report)
Date of Report: December 19, 2025
Reporting Period: Event-based (December 19, 2025)
Business Overview: The Company is an emerging growth company incorporated in Ontario, Canada, with principal executive offices in Mississauga. It trades on The Nasdaq Stock Market.
Key Financial Metrics and Transaction Details
This filing reports a capital raise event rather than periodic financial performance metrics (revenue, profit, cash flow). Key transaction figures include:
- Registered Direct Offering: Sale of 5,142,870 common shares at $7.00 per share.
- Gross Proceeds (Offering): $36 million.
- Private Placement (Canada): Up to 571,428 common shares at $7.00 per share.
- Gross Proceeds (Private Placement): Up to $4 million.
- Total Potential Gross Proceeds: Up to $40 million.
- Placement Agent Fee: 5.0% of gross proceeds from the registered direct offering.
- Legal Expense Cap: Reimbursement of legal fees up to $100,000.
Material Changes and Use of Proceeds
The primary material change is the entry into a Securities Purchase Agreement and a Placement Agency Agreement to raise capital. The filing does not provide comparative financial data versus prior periods as it is a transaction report.
Intended Use of Net Proceeds:
- Expansion of sales and marketing.
- Working capital.
- Research and development.
- Strategic transactions.
- General corporate purposes.
Guidance, Outlook, and Risks
Closing Timeline: The registered direct offering is expected to close on or about December 22, 2025. The Canadian private placement is expected to close on or prior to December 30, 2025.
Restrictions and Contingencies:
- Lock-up Period: The Company agreed to restrictions on issuing or selling common shares (or convertible securities) for 60 days following the closing of the offering.
- Private Placement Hold Period: Shares sold in the Canadian private placement are subject to a hold period of four months plus one day.
- Regulatory Approvals: The private placement is subject to necessary approvals, including conditional approval from the Toronto Stock Exchange.
- U.S. Restrictions: Private placement shares are not registered under the U.S. Securities Act and cannot be offered or sold in the U.S. absent registration or an exemption.
Management Commentary: The filing references a press release (Exhibit 99.1) for further details but does not contain specific forward-looking guidance on revenue or earnings within the text provided.
Investor Verification Checklist
- Verify the final closing date of the registered direct offering (expected Dec 22, 2025) and the private placement (expected by Dec 30, 2025).
- Confirm the exact net proceeds after deducting the 5% placement fee and legal expenses.
- Review the full text of the Securities Purchase Agreement (Exhibit 10.1) for specific covenants and representations.
- Monitor the status of the Toronto Stock Exchange approval for the Canadian private placement.
- Check subsequent filings for the actual issuance of shares and updated capitalization table.